<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01971580</url>
  </required_header>
  <id_info>
    <org_study_id>IN-US-300-D076</org_study_id>
    <nct_id>NCT01971580</nct_id>
  </id_info>
  <brief_title>The Effects of Ambrisentan on Exercise Capacity in Fontan Patients</brief_title>
  <official_title>The Effects of Ambrisentan on Exercise Capacity in Fontan Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis:

      Patients with a Fontan type palliation are limited by preload, or the rate at which blood
      returns to the heart after passively traversing the pulmonary capillary bed. By decreasing
      pulmonary vascular resistance using an endothelin receptor antagonist, both ventricular
      filling pressures and volumes will increase with a simultaneous decrease in systemic
      impedance to flow and decrease in central venous pressures, leading to an improved capacity
      to increase cardiac output, and thereby an improvement in patient functional status.

      Patients who are candidates for the study will be randomized to a double-blind single
      crossover study. Therapy with either ambrisentan or placebo will be continued for 12 weeks,
      with a 2 week washout period between treatment periods. Subjects will be subjected to a VO2
      max test to evaluate exercise capacity at enrolment, and on the last day of each treatment
      period. As a component of the VO2 max testing the patient's VE, VCO2, VE/VCO2 slope,
      ventilatory anaerobic threshold (VAT), peak work, efficiency, and other physiologic
      parameters as typically obtained from cardiopulmonary testing will be assessed. In addition,
      each patient will be asked to complete an SF-36 quality of life questionnaire at enrollment,
      and on the last day of each study period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in VO2 Max</measure>
    <time_frame>Baseline compared to 12 weeks therapy with either ambrisentan or placebo</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in Rand 36-item Short Form (SF-36) physical function score (0-100). On the Rand SF-36 questionnaire, a score closer to 100 (higher) suggests lesser disability, while a score closer to 0 (lower) suggests more disability.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Single Ventricle Fontan Palliation</condition>
  <arm_group>
    <arm_group_label>Ambrisentan first, Placebo second</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>These patients will be randomized to have ambrisentan during the first study period, and placebo during the second study period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo first, Ambrisentan second</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>These patients will be randomized to have placebo during the first study period, and ambrisentan during the second study period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ambrisentan</intervention_name>
    <arm_group_label>Ambrisentan first, Placebo second</arm_group_label>
    <arm_group_label>Placebo first, Ambrisentan second</arm_group_label>
    <other_name>Letaris</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients over 18 years of age followed at the Center for Adults with Congenital Heart
             Disease at Washington University School of Medicine or at Saint Louis Childrens
             Hospital who have had a Fontan-type of palliation with single ventricular physiology.

          2. Patients must not within the last year have been treated with an endothelin receptor
             antagonist, phosphodiesterase 5 antagonist, or prostacyclin analogue.

          3. Female patients must not be pregnant, and during the study period must be using
             effective contraception (including barrier method with spermicide, intrauterine
             device, implanon, oral contraceptives) if fertile.

          4. In the physicians opinion patients must be able to complete a VO2 max test to achieve
             an RER of &gt;1.0

          5. In the physicians opinion patients must be socially and intellectually able to adhere
             to the treatment regimen and follow-up

          6. Patients must be intellectually able to reliably complete an SF-36 questionnaire on
             quality of life.

          7. Patients must be clinically stable for at least 3 months prior to enrolment.

          8. Patients must not have had surgery within 6 months prior to enrolment, and have no
             planned surgery for the study period.

          9. Patients must provide informed consent.

        Exclusion Criteria:

          1. Patients under 18 years of age.

          2. Patients who are pregnant, nursing, or who in the physician's opinion are likely to
             become pregnant.

          3. Patients who are clinically unstable.

          4. Patients who have previously been treated with either an endothelin receptor
             antagonist and stopped due to adverse side effects.

          5. Patients with an AST or ALT of &gt;3 x normal.

          6. Patients having any known contraindication to the initiation of ambrisentan.

          7. Patients with a calculated creatinine clearance of &lt;60ml/min

          8. Patients with a serum hemoglobin concentration of &lt;10mg/dl

          9. Patients with a poorly controlled cardiac arrhythmia

         10. Patients who are unable to provide independent informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2013</study_first_submitted>
  <study_first_submitted_qc>October 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2013</study_first_posted>
  <results_first_submitted>January 23, 2018</results_first_submitted>
  <results_first_submitted_qc>May 4, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 7, 2018</results_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Ari Cedars</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ambrisentan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from Washington University School of Medicine Adult Congenital Heart Disease clinic between 10/2012 and 11/2014</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ambrisentan First, Placebo Second</title>
          <description>These patients will be randomized to have ambrisentan during the first study period, and placebo during the second study period.
Ambrisentan</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Ambrisentan Second</title>
          <description>These patients will be randomized to have placebo during the first study period, and ambrisentan during the second study period.
Ambrisentan</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ambrisentan First, Placebo Second</title>
          <description>These patients will be randomized to have ambrisentan during the first study period, and placebo during the second study period.
Ambrisentan</description>
        </group>
        <group group_id="B2">
          <title>Placebo First, Ambrisentan Second</title>
          <description>These patients will be randomized to have placebo during the first study period, and ambrisentan during the second study period.
Ambrisentan</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in VO2 Max</title>
        <time_frame>Baseline compared to 12 weeks therapy with either ambrisentan or placebo</time_frame>
        <population>In this crossover study, all patients received both ambrisentan and placebo. Data was analyzed comparing baseline measures to those after the period on ambrisentan and baseline measures to those after the period on placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>On Ambrisentan Therapy</title>
            <description>After Ambrisentan compared to baseline</description>
          </group>
          <group group_id="O2">
            <title>On Placebo</title>
            <description>After Placebo compared to baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in VO2 Max</title>
          <population>In this crossover study, all patients received both ambrisentan and placebo. Data was analyzed comparing baseline measures to those after the period on ambrisentan and baseline measures to those after the period on placebo.</population>
          <units>Change in ml/kg min</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" lower_limit="-0.92" upper_limit="3.57"/>
                    <measurement group_id="O2" value="0.745" lower_limit="-2.06" upper_limit="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life</title>
        <description>Change in Rand 36-item Short Form (SF-36) physical function score (0-100). On the Rand SF-36 questionnaire, a score closer to 100 (higher) suggests lesser disability, while a score closer to 0 (lower) suggests more disability.</description>
        <time_frame>12 weeks</time_frame>
        <population>In this crossover study, all patients received both therapies. Analysis was performed comparing baseline to after indicated therapy</population>
        <group_list>
          <group group_id="O1">
            <title>On Ambrisentan Therapy</title>
            <description>Baseline compared to after period of ambrisentan therapy</description>
          </group>
          <group group_id="O2">
            <title>On Placebo</title>
            <description>Baseline compared to after placebo therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life</title>
          <description>Change in Rand 36-item Short Form (SF-36) physical function score (0-100). On the Rand SF-36 questionnaire, a score closer to 100 (higher) suggests lesser disability, while a score closer to 0 (lower) suggests more disability.</description>
          <population>In this crossover study, all patients received both therapies. Analysis was performed comparing baseline to after indicated therapy</population>
          <units>Change in score from baseline</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.75" lower_limit="-5.78" upper_limit="13.2"/>
                    <measurement group_id="O2" value="0.195" lower_limit="-9.34" upper_limit="9.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the study period and for one month after the completion of the study protocol, an average of 30 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>On Ambrisentan Therapy</title>
          <description>Events that occurred while on ambrisentan therapy</description>
        </group>
        <group group_id="E2">
          <title>On Placebo</title>
          <description>Events that occurred while on placebo therapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis and acidosis</sub_title>
                <description>Subject developed a viral gastroenteritis not related to drug therapy which provoked drug discontinuation and hospitalization. The subject was still interested in participating and after recovering restarted the study protocol without problems.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis or Pharyngitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>cough/dyspnea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>edema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Large dropout rate. Small sample size. Many individuals did not achieve the target RER during cardiopulmonary exercise testing.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ari Cedars</name_or_title>
      <organization>UT Southwestern</organization>
      <phone>3149224788</phone>
      <email>acedars97@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

